Literature DB >> 12947082

Baseline heart rate-corrected QT and eligibility for clinical trials in oncology.

Mary Varterasian, Mark Meyer, Howard Fingert, Diane Radlowski, Peggy Asbury, Xiaofeng Zhou, Diane Healey.   

Abstract

Mesh：

Substances：

Year:  2003        PMID： 12947082     DOI： 10.1200/JCO.2003.99.104

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  14 in total

Review 1.  Prolonged QTc interval in cancer therapeutic drug development: defining arrhythmic risk in malignancy.

Authors:  Joanna M Brell
Journal:  Prog Cardiovasc Dis       Date:  2010 Sep-Oct       Impact factor: 8.194

Review 2.  Targeted Cancer Therapies and QT Interval Prolongation: Unveiling the Mechanisms Underlying Arrhythmic Complications and the Need for Risk Stratification Strategies.

Authors:  Rezarta Cuni; Iris Parrini; Riccardo Asteggiano; Maria Rosa Conte
Journal:  Clin Drug Investig       Date:  2017-02       Impact factor: 2.859

3.  Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs.

Authors:  A Naing; H Veasey-Rodrigues; D S Hong; S Fu; G S Falchook; J J Wheler; A M Tsimberidou; S Wen; S N Fessahaye; E C Golden; J Aaron; M S Ewer; R Kurzrock
Journal:  Ann Oncol       Date:  2012-06-27       Impact factor: 32.976

4.  A phase I, open-label, single-arm study for QT assessment of eribulin mesylate in patients with advanced solid tumors.

Authors:  Thierry Lesimple; Julien Edeline; Timothy J Carrothers; Frédérique Cvitkovic; Borje Darpo; Jean-Pierre Delord; Hervé Léna; Nicolas Penel; Geoff J Edwards; Kenneth Law; Jantien Wanders; Allan Kristensen; Larisa Reyderman
Journal:  Invest New Drugs       Date:  2012-11-11       Impact factor: 3.850

Review 5.  Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval).

Authors:  Rashmi R Shah; Joel Morganroth; Devron R Shah
Journal:  Drug Saf       Date:  2013-05       Impact factor: 5.606

6.  Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study.

Authors:  Tim Eisen; Yaroslav Shparyk; Nicholas Macleod; Robert Jones; Gudrun Wallenstein; Graham Temple; Yasser Khder; Claudia Dallinger; Matus Studeny; Arsene-Bienvenu Loembe; Igor Bondarenko
Journal:  Invest New Drugs       Date:  2013-04-27       Impact factor: 3.850

Review 7.  Safety biomarkers and the clinical development of oncology therapeutics: considerations for cardiovascular safety and risk management.

Authors:  Howard Fingert; Mary Varterasian
Journal:  AAPS J       Date:  2006-03-10       Impact factor: 4.009

8.  Effect of selection of QTc formula on eligibility of cancer patients for phase I clinical trials.

Authors:  Mitesh J Borad; Arundhati D Soman; Martin Benjamin; Daniel Casa; Waibhav D Tembe; Barbara F Piper; Ramesh Ramanathan; Raoul Tibes; Gayle Jameson; Karen Ansaldo; Daniel D Von Hoff
Journal:  Invest New Drugs       Date:  2012-12-16       Impact factor: 3.850

9.  QTc Interval-Prolonging Medications Among Patients With Lung Cancer: Implications for Clinical Trial Eligibility and Clinical Care.

Authors:  Tri Le; Hui Yang; Sawsan Rashdan; Mark S Link; Vlad G Zaha; Carlos Alvarez; David E Gerber
Journal:  Clin Lung Cancer       Date:  2019-11-25       Impact factor: 4.785

10.  Chemotherapy and QT Prolongation: Overview With Clinical Perspective.

Authors:  Peter Y Kim; Michael S Ewer
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.